ORIGINAL ARTICLE

Open Access

In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel

Owain Roberts

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

Search for more papers by this author

Hannah Kinvig,

Hannah Kinvig

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

Search for more papers by this author

Andrew Owen,

Andrew Owen

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, Materials Innovation Factory, University of Liverpool, Liverpool, UK

Search for more papers by this author

Mohammed Lamorde,

Mohammed Lamorde

Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda

Search for more papers by this author

Marco Siccardi,

Corresponding Author

Marco Siccardi

[email protected]

orcid.org/0000-0002-3539-7867

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

Correspondence

Marco Siccardi, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, 70 Pembroke Place, Liverpool, L69 3GF, UK.

Email: [email protected]

Search for more papers by this author

Kimberly K. Scarsi,

Kimberly K. Scarsi

College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA

Search for more papers by this author

Owain Roberts,

Owain Roberts

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

Search for more papers by this author

Hannah Kinvig,

Hannah Kinvig

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

Search for more papers by this author

Andrew Owen,

Andrew Owen

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, Materials Innovation Factory, University of Liverpool, Liverpool, UK

Search for more papers by this author

Mohammed Lamorde,

Mohammed Lamorde

Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda

Search for more papers by this author

Marco Siccardi,

Corresponding Author

Marco Siccardi

[email protected]

orcid.org/0000-0002-3539-7867

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

Correspondence

Marco Siccardi, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, 70 Pembroke Place, Liverpool, L69 3GF, UK.

Email: [email protected]

Search for more papers by this author

Kimberly K. Scarsi,

Kimberly K. Scarsi

College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA

Search for more papers by this author

First published: 30 July 2021

https://doi.org/10.1111/hiv.13136

Citations: 1

These authors contributed equally to this work.

This study was presented, in part, at the 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs. Noordwijk, The Netherlands. 14–16 May 2019 (abstract number 49).

Funding information

This study was funded by the National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development [Grant Number: 1R01HD085887 (Scarsi)]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Share a link

Email
Wechat
Bluesky

Abstract

Objectives

The World Health Organization recommends that all countries adopt dolutegravir-based antiretroviral therapy as the preferred regimen for all individuals living with HIV. Levonorgestrel is a commonly used hormonal contraceptive, which undergoes drug–drug interactions with some antiretrovirals, but the potential interaction between dolutegravir and levonorgestrel has not been examined. We aimed to evaluate cytochrome P450 (CYP)-mediated levonorgestrel metabolism and quantify the effects of dolutegravir on levonorgestrel apparent intrinsic clearance (CL_int.app.) and CYP gene expression.

Methods

In vitro CYP-mediated CL_int.app. of levonorgestrel was quantified using a recombinant human CYP (rhCYP) enzyme system. A primary human hepatocyte model of drug metabolism was used to assess the effects of dolutegravir on (1) levonorgestrel CL_int.app., using liquid chromatography-tandem mass spectrometry, and (2) the expression of specific CYP enzymes, using quantitative real-time polymerase chain reaction.

Results

Levonorgestrel clearance was mediated by multiple rhCYPs, including rhCYP3A4. Under control conditions, levonorgestrel CL_int.app. was 22.4 ± 5.0 μL/min/10⁶ hepatocytes. Incubation with 43.1 nM of unbound dolutegravir elevated levonorgestrel CL_int.app. to 31.4 ± 7.8 µL/min/10⁶ hepatocytes (P = 0.168), while 142.23 nM increased levonorgestrel CL_int.app. to 37.0 ± 2.9 µL/min/10⁶ hepatocytes (P = 0.012). Unbound dolutegravir ≥ 431 nM induced expression of CYP3A4 (≥ two-fold) in a dose-dependent manner, while 1.44 μM of unbound dolutegravir induced CYP2B6 expression 2.2 ± 0.3-fold (P = 0.0004).

Conclusions

In summary, this in vitro study suggests that dolutegravir has the potential to increase hepatic clearance of levonorgestrel by inducing both CYP3A and non-CYP3A enzymes. The observed in vitro dolutegravir–levonorgestrel drug–drug interaction should be further examined in clinical studies.

INTRODUCTION

The second-generation HIV integrase inhibitor dolutegravir, has a favourable safety profile and a low potential for drug–drug interactions (DDIs) [1]. Nevertheless, a slightly increased risk of neural tube defects occurring in the developing foetuses of women who had received dolutegravir at the time of conception, or during early pregnancy, was reported [2, 3]. The World Health Organization guidelines recommend the use of dolutegravir as first-line antiretroviral therapy (ART) in all people living with HIV, with the caveat that effective contraception should also be offered to individuals of childbearing potential, and that they should be fully informed of the potentially increased risk of neural tube defects [4].

Drug–drug interactions are known to occur between some antiretrovirals and hormonal contraceptives [5, 6]. For example, we have previously demonstrated a significant DDI between the HIV nonnucleoside reverse transcriptase inhibitor efavirenz and the levonorgestrel contraceptive implant [7]. One study has been conducted with dolutegravir and the ethinyl oestradiol/norgestimate oral contraceptive and found no evidence of DDIs [8]. Two recent studies that evaluated the combination of dolutegravir and another progestin-releasing contraceptive implant – etonogestrel – found a minimal effect in etonogestrel exposure in women receiving dolutegravir [9, 10].

There is limited mechanistic information on the pathways involved in the absorption, distribution, metabolism and excretion of steroid hormone contraceptives [11]. For example, oxidative metabolism of levonorgestrel is purported to be mediated by CYP3A4 [12, 13], but other mechanisms are also thought to play a role [14]. Levonorgestrel can be administered orally (with high bioavailability) or via subdermal implants; the volume of distribution is estimated to be between 160 and 260 L [15].

The aims of this study were to obtain in vitro data to support a better understanding of the interaction between dolutegravir and levonorgestrel by: (1) evaluating the contribution of specific key human cytochrome P450 (CYP) enzymes in levonorgestrel metabolism; (2) quantifying the effect of dolutegravir on the apparent intrinsic clearance (CL_int.app.) of levonorgestrel in a primary human hepatocyte-based in vitro model of drug metabolism; (3) quantifying the potential for dolutegravir to cause DDIs through the expression of key CYP enzymes.

METHODS

A description of the chemicals, reagents, stock solutions and primary hepatocytes used in this study is provided in the supplementary section.

Recombinant human cytochrome P450 enzyme studies and culture of cryopreserved primary human hepatocytes

The incubation method for conducting recombinant human cytochrome P450 (rhCYP) enzyme studies was adapted from Youdim et al. [16]. Cryopreserved primary human hepatocytes were cultured as described previously [17]. Following incubation for 60 min, Williams’ Medium E (WME) was removed from the cell culture plates and levonorgestrel was extracted and quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described in the supplementary methods section.

Concentrations of drugs used in this study

Primary cryopreserved hepatocytes were incubated with a range of concentrations of dolutegravir, which spanned the unbound concentration range reported in human plasma in vivo (10.3–240 ng/mL; 24.6–57.2 nM) [18]. The concentration of levonorgestrel used in hepatocyte experiments (1 nM), was selected as it was within the range of reported plasma concentrations of levonorgestrel released from Jadelle^® contraceptive subdermal implants between 1 month (1.39 nM; 435 pg/mL) and 3 years (0.90 nM; 280 pg/mL) after implant insertion [19].

The concentration of levonorgestrel used in rhCYP studies (5 µM), which is several-fold higher than would be encountered in vivo [19], was selected to ensure that substrate concentration was not a limiting factor in rhCYP reactions. This concentration was also several-fold lower than the mean observed K_m of progesterone metabolism by CYP3A4, CYP2C19 and CYP2C9 reported in analogous liver microsome studies (80, 37 and 46 µM, respectively) [20]. The degree of protein binding of dolutegravir in WME incubation medium was determined by a rapid equilibrium dialysis method and is described in the supplementary section [17].

RNA extraction, complementary DNA synthesis and quantitative real-time PCR

Total RNA was extracted from hepatocytes using the Omega BioTek E-Z 96 Total RNA kit (VWR, East Grinstead, UK). RNA quality and quantity were assessed by spectrophotometry using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). First-strand synthesis was carried out using TaqMan^® Reverse Transcription Reagents (Applied Biosystems, Waltham, MA, USA). Fold-changes in gene expression were determined as described by Pfaffl [21]. Further details are described in the supplementary methods.

Calculation of the apparent intrinsic clearance of levonorgestrel by a single recombinant human CYP

The intrinsic clearance of levonorgestrel achieved by a single rhCYP type – expressed as µL of levonorgestrel cleared/min/pmol of rhCYP (CL_int.app rhCYP) – was calculated by first calculating the rate of elimination of levonorgestrel by a single rhCYP type in terms of pmol of levonorgestrel eliminated/min/pmol of the rhCYP enzyme in question, and dividing that by the concentration of levonorgestrel (LNG in the equation) present at the start of the incubation (Eq. 1):

$urn:x-wiley:14642662:media:hiv13136:hiv13136-math-0001$ (1)

Calculation of the total intrinsic clearance of levonorgestrel by recombinant human CYP

The total intrinsic clearance of levonorgestrel achieved by a single CYP in the liver as a whole (TCL_H) was calculated using Eq. 2, as previously described [22].

$urn:x-wiley:14642662:media:hiv13136:hiv13136-math-0002$ (2)

where rhCYP abundance represents the weighted arithmetic mean abundance of the CYP of interest within in the liver (pmol/mg), as described by Achour et al. [23] ; MPPGL is the amount of microsomal protein/g of liver [24] and the liver weight is the arithmetic mean liver weight as described by Molina et al. [25]

The total apparent clearance (CL_app) of levonorgestrel by hepatic CYPs was calculated as the sum of the intrinsic clearance of each CYP quantified (Eq. 3) [22].

$urn:x-wiley:14642662:media:hiv13136:hiv13136-math-0003$ (3)

The total systemic plasma clearance (CL) was calculated from levonorgestrel CL_app as described in Eq. 4 [22]:

$urn:x-wiley:14642662:media:hiv13136:hiv13136-math-0004$ (4)

where Q_hv is the hepatic flow rate and f_u is the fraction of levonorgestrel in plasma that is unbound. As levonorgestrel is reported to be 97% bound to human plasma [26], the levonorgestrel f_u was set as 3%.

Calculation of the CL_int.app. of levonorgestrel by primary human hepatocytes

The apparent intrinsic clearance (CL_int.app.) of levonorgestrel by primary human hepatocytes was calculated based on a method described by Lu et al. [27] (Eq. 5).

$urn:x-wiley:14642662:media:hiv13136:hiv13136-math-0005$ (5)

Results were expressed as the arithmetic mean (± SD) (μL/min/10⁶ hepatocytes) of a total of three donors per condition tested. Three biological replicates were quantified for each condition, tested using cells obtained from three separate donors (HU1574, HU1587 and HU1832; Table 1).

TABLE 1. Donor demographic and medication information for cryopreserved primary human hepatocytes used

Donor	Sex	Race	Age (years)	Medications	Drug use
HU1574	Male	Caucasian	70	Atorvastatin, 80 mg q.d.; lisinopril, 5 mg q.d.; aspirin, 81 mg q.d.; Tamsulosin, 4 mg q.d.	None reported
HU1587	Female	Caucasian	43	Vitamin D oral; multivitamin oral; calcium + vitamin D + vitamin K	None reported
HU1832	Female	Caucasian	53	None reported	Alcohol and tobacco use

Note

q.d., once a day.

Statistical analysis

Statistical significance was assessed by independent-sample t-test with equal variances assumed using IBM^® SPSS^® Statistics (v.25; IBM Corporation, Armonk, NY, USA), in which P-values ≤ 0.05 were considered significant.

RESULTS

Relative contribution of specific recombinant human cytochrome P450 enzymes to levonorgestrel apparent intrinsic clearance in vitro

Given that progesterone has been reported to be metabolized by CYP3A4, CYP3A5, CYP2C9 and CYP2C19 [20, 28, 29], and that levonorgestrel is a progestin-type synthetic steroid hormone contraceptive with a chemical structure similar to that of progesterone, an assessment of potential CYP2C9- and CYP2C19-mediated metabolism of levonorgestrel was warranted, and was tested using a recombinant enzyme system involving the separate incubation of levonorgestrel with baculosomes expressing either rhCYP3A4, or rhCYP3A5, or rhCYP2C9, or rhCYP2C19 following pre-incubation with, or without, selective chemical inhibitors of each respective rhCYP.

Following incubation of levonorgestrel (5 µM) for 60 min, levonorgestrel CL_int.app. mediated by rhCYP3A4 was 0.182 ± 0.036 µL/min/pmol. Similarly, levonorgestrel CL_int.app. rhCYP3A5 was 0.178 ± 0.027 µL/min/pmol following incubation with rhCYP3A5 [30]. Incubation of levonorgestrel with rhCYP2C9 resulted in a levonorgestrel CL_int.app. rhCYP2C9 of 0.062 ± 0.010 µL/min/pmol [16, 31] while levonorgestrel CL_int.app. rhCYP2C19 was 0.046 ± 0.005 µL/min/pmol. CYP1A2 and CYP2B6 have important roles in drug metabolism [32] and have also been implicated in steroid hormone metabolism, including the metabolism of testosterone [33] (CYP2B6), oestradiol and oestrone [34] (CYP2B6), and a minor role for CYP1A2 in mediating progesterone metabolism [28]. It was therefore of interest to determine the potential role of rhCYP1A2 and rhCYP2B6 in levonorgestrel metabolism. Levonorgestrel CL_int.app. rhCYP1A2 was 0.028 ± 0.012 µL/min/pmol [35]. Levonorgestrel CL_int.app. rhCYP2B6 resulted in a levonorgestrel clearance rate of 0.052 ± 0.004 µL/min/pmol [36].

Next, the in vitro CL_int.app. rhCYP clearance rates obtained for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4 and CYP3A5 were used to estimate the total intrinsic clearance of levonorgestrel that would be achieved by each respective single CYP in the adult female liver as a whole (TCL_H) (Eq. 2). The largest TCL_H observed was that of CYP3A4, with a TCL_H of 52.5 ± 10.4 L/h (Figure 1). The TCL_H values of CYP3A5 and CYP2C9 were 9.4 ± 1.4 and 11.6 ± 1.9 L/h, respectively (Figure 1). By comparison, the relative contributions of CYP1A2, CYP2B6 and CYP2C19 to levonorgestrel TCL_H were 3.4 ± 1.5, 2.6 ± 0.2 and 1.6 ± 0.2 L/h, respectively (Figure 1).

Details are in the caption following the image — **FIGURE 1**
Open in figure viewer PowerPoint

Predicted contribution of cytochrome P450 (CYP) enzymes to the total intrinsic clearance of levonorgestrel in the female liver. Baculosomes^® expressing recombinant human cytochrome P450 (rhCYP) enzymes (rhCYP1A2, rhCYP2B6, rhCYP2C9, rhCYP2C19, rhCYP3A4 or rhCYP3A5) were incubated for 60 min at 37℃ with levonorgestrel (LNG; 5 µM) alone (test samples), or were pre-incubated for 15 min each at 37℃ with the following CYP inhibitors – α-naphthoflavone (3 µM; CYP1A2 inhibitor); sertraline (16 µM; CYP2B6 inhibitor); sulfaphenazole (10 µM; CYP2C9 inhibitor); (+)-N-3-benzylnirvanol (10 µM; CYP2C19 inhibitor); ketoconazole (10 µM; CYP3A4 inhibitor); or ketoconazole (30 µM; CYP3A5 inhibitor) – prior to incubation with levonorgestrel (5 µM) at 37℃ for 60 min (inhibitor control samples). The amount of levonorgestrel present following incubation with levonorgestrel for 60 min was quantified by high-performance liquid chromatography-UV at 230 nm. Levonorgestrel clearance by individual rhCYPs was calculated by comparing levonorgestrel concentrations in test samples with those of respective inhibitor control samples. The obtained clearance values were subsequently scaled up as described in the text (Eq. 2) [22] to predict the total intrinsic clearance of levonorgestrel achieved by a single CYP in the female liver as a whole (TCL_H). The values shown are the arithmetic mean of three independent experiments performed in triplicate. Error bars represent SD

The total apparent clearance (CL_app) of levonorgestrel by the hepatic CYPs measured was 80.97 ± 15.53 L/h, and the total systemic plasma clearance of levonorgestrel was 2.38 ± 0.46 L/h.

Effects of dolutegravir on the apparent intrinsic clearance of levonorgestrel

The use of cryopreserved human hepatocytes is a recommended method for assessing metabolism-based DDIs in vitro [37]. As such, the effect of dolutegravir on levonorgestrel CL_int.app. by cryopreserved primary human hepatocytes obtained from three different donors (HU1574, HU1587 and HU1832) was quantified. Under control conditions, where hepatocytes were incubated with 1 nM levonorgestrel alone, levonorgestrel CL_int.app. was 22.4 ± 5.0 µL/min/10⁶ cells. Rifampin was used as a positive control to induce levonorgestrel CL_int.app. by hepatocytes. Incubation with 10 µM rifampin has previously been shown to optimally induce CYP3A4 enzymatic activity in hepatocytes in vitro [38, 39], including achieving the maximal CL_int.app. of CYP3A4 substrates in this model [17]. As expected, incubation with 10 µM rifampin for 72 h increased levonorgestrel CL_int.app. by 109%, to 46.7 ± 6.9 µL/min/10⁶ cells (P = 0.008; Figure 2).

The median unbound dolutegravir (DTG_unbound) reported in human plasma is 24.6–57.2 nM [18]. We selected concentrations of DTG_unbound to span this range when assessing the effects of dolutegravir on levonorgestrel CL_int.app.. Quantification of the amount of protein-binding of dolutegravir within our hepatocyte-based model of drug metabolism showed that the unbound fraction (f_u) of dolutegravir in WME incubation medium was 0.43 ± 0.09 (n = 9). A levonorgestrel CL_int.app. of 34.5 ± 9.2 µL/min/10⁶ cells (P = 0.114; Figure 2) was observed following 72 h incubation with 0.033 µM dolutegravir (DTG_unbound = 14.2 nM). A trend towards elevated levonorgestrel CL_int.app. was apparent at all concentrations of dolutegravir tested, with 0.1 µM dolutegravir (DTG_unbound = 43.1 nM), resulting in a levonorgestrel CL_int.app. of 31.4 ± 7.8 µL/min/10⁶cells (P = 0.168; Figure 2). Incubation of hepatocytes with 0.33 µM dolutegravir (DTG_unbound = 142.23 nM) and 3.33 µM dolutegravir (DTG_unbound = 1.44 µM) for 72 h significantly increased levonorgestrel CL_int.app. to 37.0 ± 2.9 µL/min/10⁶cells (P = 0.012),= and 32.8 ± 4.2 µL/min/10⁶cells (P = 0.050), respectively (Figure 2).

Analysis of the effects of dolutegravir on the expression of CYP1A2, CYP2B6 and CYP3A4 in human hepatocytes

United States Food and Drug Administration guidelines recommend evaluation of the potential of an investigational drug to induce CYP1A2, CYP2B6 and CYP3A4 [37]. To evaluate the potential of dolutegravir to induce CYP expression, an in vitro gene expression assay in human hepatocytes was used to assess the effects of incubating a range of concentrations of dolutegravir (0.00033–10 μM; DTG_unbound, 0.142–4310 nM) on the expression of CYP1A2, CYP2B6 and CYP3A4. Also, hepatocytes were incubated separately with phenobarbital (1 mM) – a positive control for induction of the expression of CYP1A2 [40] and CYP2B6 [41] – as well as rifampin (10 µM), which served as a positive control for the induction of the expression of CYP2B6 [41], and CYP3A4 [38, 42].

Although incubation with the CYP1A2 inducer phenobarbital (1 mM) induced CYP1A2 expression by 2.7 ± 0.6-fold (P = 0.043; Figure 3a), dolutegravir did not induce the expression of CYP1A2 (by ≥ two-fold above vehicle control) at any of the concentrations tested (Figure 3a). By contrast, incubation with a total dolutegravir concentration of 3.33 µM (DTG_unbound = 1.44 µM) and 10 μM (DTG_unbound = 4.310 µM) induced the expression of CYP2B6 by 2.2 ± 0.3-fold and 2.3 ± 0.7-fold, respectively (Figure 3b). Under the same conditions, phenobarbital (1 mM) induced CYP2B6 expression by 2.6 ± 1.1-fold (Figure 3b), while rifampin (10 µM) induced CYP2B6 expression by 2.0 ± 0.5-fold (Figure 3b).

Incubation with rifampin (10 µM) induced a 7.7 ± 1.9-fold increase in CYP3A4 expression, while incubation with phenobarbital (1 mM) elevated CYP3A4 expression levels 4.8 ± 0.7-fold (Figure 3c). Incubation with DTG_unbound = 431 nM (total dolutegravir concentration of 1 μM), significantly induced expression of CYP3A4 by 2.3 ± 0.4-fold (Figure 3c). Dolutegravir-induced expression of CYP3A4 increased in a dose-dependent manner, with 3.33 μM dolutegravir (DTG_unbound = 1.44 μM) resulting in a 3.5 ± 0.7-fold induction of CYP3A4 expression, and 10 μM dolutegravir (DTG_unbound 4.31 μM) eliciting a 4.1 ± 1.0-fold induction (Figure 3c).

DISCUSSION

The need to assess the likelihood of DDIs occurring between antiretrovirals and hormonal contraceptives has recently been highlighted [43]. However, the mechanistic potential for DDIs between dolutegravir and levonorgestrel had not been previously examined. Furthermore, a paucity of information existed regarding the metabolic pathways mediating levonorgestrel metabolism. Here, it was found that rhCYP3A4 was the predominant CYP mediating apparent clearance of levonorgestrel (Figure 1), a finding that supports the established view that CYP3A4 is an important mediator of levonorgestrel metabolism [12, 13]. Interestingly, secondary to CYP3A4, both CYP2C9 and CYP3A5 mediated apparent clearance of levonorgestrel to a similar degree (Figure 1). Meanwhile, CYP1A2, CYP2B6 and CYP2C19 each had relatively minor roles as mediators of levonorgestrel clearance (Figure 1).

It was recently concluded that CYP3A may not represent the predominant pathway by which levonorgestrel is metabolized [11]. A recently published study examining the effects of rifampin on the pharmacokinetics of various progestin-based oral contraceptives showed that exogenous progestins exhibited differential vulnerability to rifampin-mediated CYP3A4 induction [14], and that levonorgestrel was among the least vulnerable progestins to rifampin-induced CYP3A4 activity. The present study supports this observation, showing a predominant, but not exclusive, role for CYP3A4 in mediating levonorgestrel metabolism [14]. CYP3A4 is the predominant CYP involved in progesterone metabolism [20, 28, 29], and our findings reveal that the CYPs involved in metabolism of levonorgestrel share some similarity with CYP-mediated progesterone metabolism pathways, where CYP1A2 [28], CYP2C9 [20, 28] and CYP2C19 [20, 28] each has a contributory role, secondary to CYP3A4. It remains possible, therefore, that other CYPs may also contribute to levonorgestrel metabolism. Indeed, a role for CYP3A7 – the predominant foetal isoform of CYP3A enzymes – as an important mediator of etonogestrel metabolism, was recently described [44]. Levonorgestrel implants are contraindicated in women receiving antiepileptic drugs due to the potential for DDIs that may result in contraceptive failure [45]. Notwithstanding the CYP3A induction potential of the antiepileptic drugs phenytoin and oxcarbazepine, phenytoin–levonorgestrel and oxcarbazepine-levonorgestrel DDIs may be mediated by non-CYP3A enzymes [46, 47]. Indeed, this further underlines the recently reviewed general need to better define the pharmacokinetics of mixed-mechanism DDIs [48]. While administering CYP3A inducers can decrease systemic levonorgestrel exposure by > 40% in vivo [11], it has been highlighted that the CYP3A inducers used when conducting these studies also have the potential to induce the expression of other enzymes, including phase II enzymes, together with multiple phase I enzymes, and drug transporters [11]. Although assessing the relative contribution of phase II enzymes and drug transporters in levonorgestrel clearance was beyond the scope of the current study, this should be addressed in future in vitro studies in order to better evaluate the DDI vulnerability of levonorgestrel.

The total systemic plasma clearance of levonorgestrel was estimated to be 2.38 ± 0.46 L/h. The total clearance of levonorgestrel by various routes of administration in adult females ranges between 3.9 and 4.2 L/h [15, 49]. The reasons for these differential values may be explained by the following: (1) the potential contribution of CYPs other than rhCYP1A2, rhCYP2B6, rhCYP2C9, rhCYP2C19, rhCYP3A4 and rhCYP3A5 were not quantified in the present study; (2) the potential contribution of phase II enzymes and drug transporters were not considered when estimating levonorgestrel total systemic plasma clearance using rhCYP data herein; (3) the potential contribution of extrahepatic metabolism of levonorgestrel was not considered; (4) the likely effects of interindividual variability in CYP expression and other pharmacokinetic parameters were not considered; (5) in vitro rhCYP systems are known to frequently underestimate drug clearance and may differ from the individuals included in the reported studies; and (6) the integration of protein binding in our calculation could differ from the clinical studies used for the comparison [50, 51].

The potential for dolutegravir to cause a DDI was measured by quantifying the effects of dolutegravir on the expression of CYP1A2, CYP2B6 and CYP3A4 [52]. At unbound dolutegravir concentrations ≥ 7.5-fold higher than have been reported in plasma, dolutegravir induced the expression of CYP2B6 and CYP3A4, but did not induce increased expression of CYP1A2 (Figure 3). The observed effects of dolutegravir on gene expression contradict a previous study [53], which suggested that expression of neither CYP2B6 nor CYP3A4 was affected at total dolutegravir concentrations up to and including 40 µM [53]. The reasons for these differences are not known, but may be due to inter-donor variation in the hepatocytes, or to differences in the duration of incubation with dolutegravir with hepatocytes (48 h [53] vs. 72 h in the present study). Indeed, while incubation of hepatocytes with test compounds for either 48 or 72 h are both recommended for in vitro assessment of the induction potential of compounds [52], consideration should be given to the fact that chronically administered drugs, including dolutegravir, will be administered in vivo for prolonged periods of time. Furthermore, studies using prototypic inducers of CYP expression have shown that temporal differences can lead to differential expression of key drug-metabolizing CYPs [41, 54, 55]. Nevertheless, at concentrations spanning the range of unbound concentrations of dolutegravir reported in human plasma (10.3–240 ng/mL; 24.6–57.2 nM [18] ) dolutegravir had no effect on the expression of CYP2B6 or CYP3A4 in the present study (Figure 3). CYP2C9 is characterized by lower (two- to three-fold), but correlated, inducibility compared with CYP3A4, and, consequently, it is likely that at relevant dolutegravir concentrations CYP2C9 does not play a significant role in this interaction [56].

In vitro data was used to describe the combination of dolutegravir and levonorgestrel implants by quantifying the effects of dolutegravir on levonorgestrel CL_int.app.. Using an in vitro hepatocyte-based model of drug metabolism [17], the incubation with rifampin increased levonorgestrel clearance by 109%, and this experimental effect is comparable to clinical observation, where levonorgestrel exposure was decreased by 58% [14]. Incubation with dolutegravir at concentrations spanning the range of median DTG_unbound in plasma (10.3–240 ng/mL; 24.6–57.2 nM) [18] resulted in a trend towards elevated levonorgestrel CL_int.app. (Figure 2). Therefore, while these observations show that a DDI exists between dolutegravir and levonorgestrel in vitro, it remains unclear whether a dolutegravir–levonorgestrel DDI may occur with the DTG_unbound plasma concentrations encountered in vivo.

In summary, this study reveals novel CYP-mediated mechanisms of levonorgestrel metabolism, supporting the notion that levonorgestrel undergoes metabolism by CYP enzymes additional to CYP3A, and shows that incubation with dolutegravir can significantly elevate levonorgestrel CL_int.app. and expression of CYP2B6 and CYP3A4, albeit at concentrations greater than the clinical therapeutic range of dolutegravir in humans, raising the possibility that clinical dolutegravir–levonorgestrel DDIs may occur. Future studies should aim to further elucidate the mechanisms mediating levonorgestrel metabolism in vitro, and clinical studies should aim to evaluate the effects of dolutegravir on levonorgestrel exposure in humans to ensure their safe and effective combination for females living with HIV.

AUTHOR CONTRIBUTIONS

OR, MS, AO, KKS and HK participated in designing the research. OR and HK conducted experiments. OR, HK and MS performed the data analysis. OR, HK, AO, ML, KKS and MS contributed to the writing of the manuscript.

Supporting Information

REFERENCES

1Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 2013; 52: 981-994.
10.1007/s40262-013-0093-2
CAS PubMed Web of Science® Google Scholar
2Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018; 379: 979-981.
10.1056/NEJMc1807653
PubMed Web of Science® Google Scholar
3 World Health Organisation. Potential safety issue affecting women living with HIV using dolutegravir at the time of conception. Geneva, Switzerland, 2018.
Google Scholar
4 World Health Organisation. Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland, 2019.
Google Scholar
5Robinson JA, Jamshidi R, Burke AE. Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy. Infect Dis Obstet Gynecol. 2012; 2012: 890160.
10.1155/2012/890160
CAS PubMed Google Scholar
6Nanda K, Stuart GS, Robinson J, Gray AL, Tepper NK, Gaffield ME. Drug interactions between hormonal contraceptives and antiretrovirals. AIDS 2017; 31: 917-952.
10.1097/QAD.0000000000001392
PubMed Web of Science® Google Scholar
7Scarsi KK, Darin KM, Nakalema S, et al. Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks. Clin Infect Dis 2016; 62: 675-682.
10.1093/cid/civ1001
CAS PubMed Web of Science® Google Scholar
8Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC. Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol. Ann Pharmacother 2015; 49: 784-789.
10.1177/1060028015580637
CAS PubMed Web of Science® Google Scholar
9Bishop IJ, Gertz AM, Simon B, et al. Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy. Contraception 2020; 102: 174-179.
10.1016/j.contraception.2020.04.019
CAS PubMed Web of Science® Google Scholar
10Patel R, Stalter R, Onono M, et al. Dolutegravir-containing ART does not reduce etonogestrel implant concentrations. Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2020.
Google Scholar
11Zhang N, Shon J, Kim MJ, et al. Role of CYP3A in oral contraceptives clearance. Clin Transl Sci 2018; 11: 251-260.
10.1111/cts.12499
PubMed Web of Science® Google Scholar
12 Bayer New Zealand Limited. Jadelle^®, Subcutaneous Implants, Levonorgestrel 2 x 75 mg, Data Sheet. 2015. http://www.medsafe.govt.nz/Profs/Datasheet/j/Jadelleimplant.pdf. Accessed 9 November 2020.
Google Scholar
13 Food and Drug Administration. Highlights of Prescribing Information - JADELLE (levonorgestrel implants) for subdermal use. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020544s010lbl.pdf. Accessed 9 November 2020.
Google Scholar
14Wiesinger H, Klein S, Rottmann A, et al. The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam. Clin Pharmacol Ther 2020; 108: 798-807.
10.1002/cpt.1848
CAS PubMed Web of Science® Google Scholar
15Kook K, Gabelnick H, Duncan G. Pharmacokinetics of levonorgestrel 0.75 mg tablets. Contraception 2002; 66: 73-76.
10.1016/S0010-7824(02)00321-9
CAS PubMed Web of Science® Google Scholar
16Youdim KA, Zayed A, Dickins M, et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 2008; 65: 680-692.
10.1111/j.1365-2125.2007.03070.x
CAS PubMed Web of Science® Google Scholar
17Roberts O, Khoo S, Owen A, Siccardi M. Interaction of rifampin and darunavir-ritonavir or darunavir-cobicistat in vitro. Antimicrob Agents Chemother 2017; 61.
10.1128/AAC.01776-16
Web of Science® Google Scholar
18 Food and Drug Administration. Dolutegravir, GSK1349572, Clinical Pharmacology Review. 2012. https://www.fda.gov/downloads/Drugs/…/UCM370760.pdf. Accessed 04 April 2019.
Google Scholar
19Sivin I, Wan L, Ranta S, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception 2001; 64: 43-49.
10.1016/S0010-7824(01)00226-8
CAS PubMed Web of Science® Google Scholar
20Yamazaki H, Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 1997; 346: 161-169.
10.1006/abbi.1997.0302
CAS PubMed Web of Science® Google Scholar
21Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
10.1093/nar/29.9.e45
CAS PubMed Web of Science® Google Scholar
22Rajoli RK, Back DJ, Rannard S, et al. Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV. Clin Pharmacokinet 2015; 54: 639-650.
10.1007/s40262-014-0227-1
CAS PubMed Web of Science® Google Scholar
23Achour B, Barber J, Rostami-Hodjegan A. Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis. Drug Metab Dispos 2014; 42: 1349-1356.
10.1124/dmd.114.058834
PubMed Web of Science® Google Scholar
24Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos 2008; 36: 2405-2409.
10.1124/dmd.108.021311
CAS PubMed Web of Science® Google Scholar
25Molina DK, DiMaio VJ. Normal organ weights in women: part ii-the brain, lungs, liver, spleen, and kidneys. Am J Forensic Med Pathol 2015; 36: 182-187.
10.1097/PAF.0000000000000175
PubMed Web of Science® Google Scholar
26Qi-Gui L, Hümpel M. Serum protein binding characteristics of cyproterone acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man. J Steroid Biochem 1990; 35: 319-326.
10.1016/0022-4731(90)90291-Y
PubMed Web of Science® Google Scholar
27Lu C, Li P, Gallegos R, et al. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 2006; 34: 1600-1605.
10.1124/dmd.106.010793
CAS PubMed Web of Science® Google Scholar
28Niwa T, Yabusaki Y, Honma K, et al. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica 1998; 28: 539-547.
10.1080/004982598239290
CAS PubMed Web of Science® Google Scholar
29Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991; 290: 160-166.
10.1016/0003-9861(91)90602-F
CAS PubMed Web of Science® Google Scholar
30Stresser DM, Broudy MI, Ho T, et al. Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 2004; 32: 105-112.
10.1124/dmd.32.1.105
CAS PubMed Web of Science® Google Scholar
31Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996; 277: 321-332.
CAS PubMed Web of Science® Google Scholar
32Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141.
10.1016/j.pharmthera.2012.12.007
CAS PubMed Web of Science® Google Scholar
33Rendic S, Nolteernsting E, Schanzer W. Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl 1999; 735: 73-83.
10.1016/S0378-4347(99)00400-4
CAS PubMed Web of Science® Google Scholar
34Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 1998; 11: 659-665.
10.1021/tx970217f
CAS PubMed Web of Science® Google Scholar
35Cho US, Park EY, Dong MS, Park BS, Kim K, Kim KH. Tight-binding inhibition by alpha-naphthoflavone of human cytochrome P450 1A2. Biochim Biophys Acta 2003; 1648: 195-202.
10.1016/S1570-9639(03)00148-1
CAS PubMed Web of Science® Google Scholar
36Melis V, Usach I, Gandia P, Peris JE. Inhibition of efavirenz metabolism by sertraline and nortriptyline and their effect on efavirenz plasma concentrations. Antimicrob Agents Chemother 2016; 60: 1022-1028.
10.1128/AAC.02129-15
CAS PubMed Web of Science® Google Scholar
37 Food and Drug Administration. In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. 2020. https://www.fda.gov/media/134582/download. Accessed 9 November 2020.
Google Scholar
38Fahmi OA, Kish M, Boldt S, Obach RS. Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 2010; 38: 1605-1611.
10.1124/dmd.110.033126
CAS PubMed Web of Science® Google Scholar
39Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44: 1273-1281.
10.1177/0091270004269142
CAS PubMed Web of Science® Google Scholar
40Yoshinari K, Yoda N, Toriyabe T, Yamazoe Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'-flanking region. Biochem Pharmacol 2010; 79: 261-269.
10.1016/j.bcp.2009.08.008
CAS PubMed Web of Science® Google Scholar
41Faucette SR, Wang H, Hamilton GA, et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004; 32: 348-358.
10.1124/dmd.32.3.348
CAS PubMed Web of Science® Google Scholar
42Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-832.
10.1124/dmd.31.7.815
CAS PubMed Web of Science® Google Scholar
43Ahn MR, Li L, Shon J, Bashaw ED, Kim MJ. Teratogenic drugs and their drug interactions with hormonal contraceptives. Clin Pharmacol Ther 2016; 100: 217-219.
10.1002/cpt.384
CAS PubMed Web of Science® Google Scholar
44Lazorwitz A, Aquilante CL, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of genetic variants on steady-state etonogestrel concentrations among contraceptive implant users. Obstet Gynecol 2019; 133: 783-794.
10.1097/AOG.0000000000003189
CAS PubMed Web of Science® Google Scholar
45Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263-272.
10.2165/00023210-200216040-00005
CAS PubMed Web of Science® Google Scholar
46Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30: 892-896.
10.1111/j.1365-2125.1990.tb05457.x
CAS PubMed Web of Science® Google Scholar
47Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783-787.
10.1111/j.1528-1157.1999.tb00779.x
CAS PubMed Web of Science® Google Scholar
48Ramsden D, Fung C, Hariparsad N, et al. Perspectives from the innovation and quality consortium induction working group on factors impacting clinical drug-drug interactions resulting from induction: focus on cytochrome 3A substrates. Drug Metab Dispos 2019; 47: 1206-1221.
10.1124/dmd.119.087270
CAS PubMed Web of Science® Google Scholar
49Reinecke I, Hofmann B, Mesic E, Drenth HJ, Garmann D. An Integrated population pharmacokinetic analysis to characterize levonorgestrel pharmacokinetics after different administration routes. J Clin Pharmacol 2018; 58: 1639-1654.
10.1002/jcph.1288
CAS PubMed Web of Science® Google Scholar
50Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 2009; 37: 1025-1034.
10.1124/dmd.108.024810
CAS PubMed Web of Science® Google Scholar
51Galetin A, Brown C, Hallifax D, Ito K, Houston JB. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab Dispos 2004; 32: 1411-1420.
10.1124/dmd.104.000844
CAS PubMed Web of Science® Google Scholar
52 Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. 2017. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table1. Accessed 9 November 2020.
Google Scholar
53Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 2013; 41: 353-361.
10.1124/dmd.112.048918
CAS PubMed Web of Science® Google Scholar
54Zhang JG, Ho T, Callendrello AL, Crespi CL, Stresser DM. A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with beta-naphthoflavone, phenobarbital and rifampicin. Drug Metab Lett 2010; 4: 185-194.
10.2174/187231210792928224
CAS PubMed Google Scholar
55LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, Parkinson A. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2000; 14: 177-188.
10.1002/(SICI)1099-0461(2000)14:4<177::AID-JBT1>3.0.CO;2-4
CAS PubMed Web of Science® Google Scholar
56Endo-Tsukude C, Kato M, Kaneko A, et al. Risk of CYP2C9 induction analyzed by a relative factor approach with human hepatocytes. Drug Metab Pharmacokinet 2019; 34: 325-333.
10.1016/j.dmpk.2019.07.002
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume22, Issue10

November 2021

Pages 898-906

In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel